青少年起病1型糖尿病的胰岛自身免疫特征与临床及遗传相关性
该横断面研究对80例青少年起病1型糖尿病患者进行HLA基因分型、基于93个非HLA SNP的遗传风险评分及T细胞增殖试验,发现67例对一种以上胰岛抗原有增殖反应,可聚类为非、中、高反应者;高反应者非HLA遗传风险评分显著更高,但高T细胞反应未反映为血糖控制恶化、并发症增加、相关自身免疫发生或发病年龄更早。
要点
- 67/80例对一种以上胰岛抗原有T细胞增殖反应,反应强度差异大,可聚类为非、中、高反应者。
- 高反应者非HLA遗传风险评分显著更高,但不能完全由最高风险HLA-DR3-DQ2/DR4-DQ8基因型解释。
- 高T细胞反应未反映为血糖控制恶化、并发症增加、相关自身免疫发生或发病年龄更早。
核心结论
- 青少年起病1型糖尿病存在免疫、遗传和临床异质性,高胰岛自身免疫反应者以非HLA遗传风险评分更高为特征。
- 高T细胞反应未反映为更差的血糖控制、并发症、相关自身免疫或更早发病年龄。
- 对β细胞抗原的T细胞反应数量随病程延长而增加,提示慢性胰岛自身免疫和表位扩展。
研究设计与样本
- 横断面研究,纳入80例青少年起病1型糖尿病患者。
- 参与者接受HLA基因分型以确定HLA-DR-DQ风险,并接受SNP基因分型以基于MHC区域外93个1型糖尿病相关SNP变异生成非HLA遗传风险评分。
- 胰岛自身免疫通过β细胞抗原GAD65、IA-2、PPI和INS-DRIP刺激后的T细胞增殖评估,临床参数回顾性收集。
主要发现
- 80例中67例对一种或多种胰岛抗原出现增殖反应,增殖程度差异很大。
- 根据增殖反应的数量和幅度,个体被聚类为非反应者、中间反应者和高反应者。
- 高反应者不能完全由最高风险HLA-DR3-DQ2/DR4-DQ8基因型富集来表征,但其非HLA遗传风险评分显著更高。
- 高T细胞反应未反映为血糖控制恶化、并发症增加、相关自身免疫发生或发病年龄更早。
- 个体对β细胞抗原的反应数量随病程延长而增加,提示慢性胰岛自身免疫和表位扩展。
临床怎么用
- 可依据遗传和自身免疫特征对1型糖尿病患者进行分层,以支持免疫治疗和个性化疾病管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Heterogeneity in individuals with type 1 diabetes has become more generally appreciated, but has not yet been extensively and systematically characterised. Here, we aimed to characterise type 1 diabetes heterogeneity by creating immunological, genetic and clinical profiles for individuals with juvenile-onset type 1 diabetes in a cross-sectional study. METHODS: Participants were HLA-genotyped to determine HLA-DR-DQ risk, and SNP-genotyped to generate a non-HLA genetic risk score (GRS) based on 93 type 1 diabetes-associated SNP variants outside the MHC region. Islet autoimmunity was assessed as T cell proliferation upon stimulation with the beta cell antigens GAD65, islet antigen-2 (IA-2), preproinsulin (PPI) and defective ribosomal product of the insulin gene (INS-DRIP). Clinical parameters were collected retrospectively. RESULTS: Of 80 individuals, 67 had proliferation responses to one or more islet antigens, with vast differences in the extent of proliferation. Based on the multitude and amplitude of the proliferation responses, individuals were clustered into non-, intermediate and high responders. High responders could not be characterised entirely by enrichment for the highest risk HLA-DR3-DQ2/DR4-DQ8 genotype. However, high responders did have a significantly higher non-HLA GRS. Clinically, high T cell responses to beta cell antigens did not reflect in worsened glycaemic control, increased complications, development of associated autoimmunity or younger age at disease onset. The number of beta cell antigens that an individual responded to increased with disease duration, pointing to chronic islet autoimmunity and epitope spreading. CONCLUSIONS/INTERPRETATION: Collectively, these data provide new insights into type 1 diabetes disease heterogeneity and highlight the importance of stratifying patients on the basis of their genetic and autoimmune signatures for immunotherapy and personalised disease management.
引用
- Claessens LA, Wesselius J, van Lummel M, et al. Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes. Diabetologia. 2019. PMID: 31754749. doi:10.1007/s00125-019-05032-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。